Screener
Candel Therapeutics, Inc. CADL Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-222904
FAQ
- What is Candel Therapeutics, Inc.'s restricted cash?
- Candel Therapeutics, Inc. (CADL) reported restricted cash of $416K in Q1 2026.
- How has Candel Therapeutics, Inc.'s restricted cash changed year-over-year?
- Candel Therapeutics, Inc.'s restricted cash increased by 56.4% year-over-year, from $266K to $416K.
- What is the long-term trend for Candel Therapeutics, Inc.'s restricted cash?
- Over 4 years (2021 to 2025), Candel Therapeutics, Inc.'s restricted cash has grown at a -0.5% compound annual growth rate (CAGR), from $424K to $416K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Candel Therapeutics, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude